Pallas Health vs Wellmedr: Prices, meds, and plan differences
Pallas Health vs Wellmedr answer: both offer online GLP-1 options, but Pallas centers on clinician choice between FDA-approved brand pens and U.S.-compounded preparations while WellMedr emphasizes low starting prices and lifetime locked-in pricing. Early verdict: choose Pallas if you want a clinician to pick brand-name or compounded medication as part of one all-in plan; choose WellMedr if lowest advertised monthly starts and lifetime price locking are your priority.
Start Pallas intake and clinician review
How they compare at a glance: methods, pricing model, and shipping
Both providers offer online clinician review and compounded options, but the differences show in price structure, medication selection, and shipping or refill promises. Use the table below to compare core criteria captured in the source material.
| Criteria | Pallas Health | WellMedr |
|---|---|---|
| Starting price (compounded semaglutide) | $139 first month; then $597 every 12 weeks ($199/mo avg) | Semaglutide plans starting at $49/mo or $89/mo depending on plan |
| Brand-name availability | Offers FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro when appropriate | Lists brand options such as Ozempic and Zepbound at separate starting prices |
| Compounded medication note | Compounded in the USA; not FDA-approved; prepared by US-licensed compounding pharmacies | Compounded from licensed U.S. pharmacies; not evaluated by FDA |
| Pricing model and renewals | One all-in plan price; compounded plans priced by medication not by milligram; renew every 12 weeks | Lifetime locked-in pricing available; no dose-based price increases; monthly shipping options |
| Shipping and refill promise | Free expedited, discreet shipping; self-serve portal for refills | Same-day review and free overnight shipping; on-time refills guaranteed |
Distinctive difference 1: clinician-led brand choice vs locked pricing focus
Pallas Health highlights clinician selection between FDA-approved brand-name pens and U.S.-compounded semaglutide or tirzepatide as a defining feature. WellMedr centers marketing on low starting monthly figures and lifetime locked-in pricing. The source states Pallas offers FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro and clinician-personalized compounded options. The source states WellMedr offers “Lifetime locked-in pricing” and “GLP-1 Plans Starting at Just $89/Month.”
Distinctive difference 2: pricing cadence and renewal terms
Pallas prices its compounded plans by medication rather than by milligram, with compounded semaglutide described as $139 for the first month then $597 every 12 weeks, a $199/month average; compounded tirzepatide is $179 then $897 every 12 weeks ($299/mo avg). Pallas notes plans renew every 12 weeks. WellMedr presents monthly plans and promotional offers such as a Labor Day Sale and lifetime offers; captured copy lists semaglutide starting at $49/mo on certain plans and tirzepatide starting at $89/mo with monthly shipments. The sources emphasize different billing rhythms: multiweek renewals for Pallas and month-to-month for WellMedr.
See Pallas pricing and plan details
Distinctive difference 3: shipping, review speed and refill guarantees
Pallas promises free expedited and discreet shipping and a self-serve portal for refills, with eligibility determined by a U.S.-licensed clinician and care-team hours weekdays 9 AM–5 PM ET. WellMedr advertises same-day review plus free overnight shipping and an on-time refills guarantee. The source materials present Pallas as emphasizing clinician review and included provider care, while WellMedr emphasizes speed and refill timing commitments.
Safety and regulatory language both share
Both sources include a regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas explicitly notes compounded medications are prepared by U.S.-licensed compounding pharmacies and that Pallas does not manufacture or compound medication. WellMedr states compounded medications are regulated by state Boards of Pharmacy but are not evaluated by the FDA. Both require medical evaluation and clinician approval.
Check WellMedr plans and locked pricing
How provider features affect choice
If you need clinician guidance about choosing between brand-name pens and a compounded preparation, the source frames Pallas Health as built for that workflow and bundles provider care into the plan price with no membership fee. If your priority is the lowest advertised monthly start and a lifetime locked price or explicit same-day review and refill guarantees, the source frames WellMedr around those selling points. Neither source in the provided material guarantees specific weight-loss outcomes; WellMedr includes a promotional money-back statement in its captured copy and attributes clinical outcomes to published research rather than provider-specific results.
View WellMedr monthly plans and offers
Bottom line and final guidance on Pallas Health vs Wellmedr
Both Pallas Health and WellMedr offer online clinician evaluation and access to compounded GLP-1s, but the sources emphasize different priorities: Pallas emphasizes clinician selection between brand-name and compounded options and an all-in plan price structure with 12-week compound renewals; WellMedr emphasizes low starting monthly pricing, lifetime locked-in pricing, same-day review and on-time refill guarantees. The primary keyword Pallas Health vs Wellmedr reflects these contrasts directly.
Choose Pallas Health if you want a clinician to choose between FDA-approved brand-name GLP-1 pens and a U.S.-compounded semaglutide or tirzepatide within an all-in plan that includes provider care and uses 12-week compounded renewals.
Choose WellMedr if you prioritize the lowest advertised monthly starts, lifetime locked-in pricing or the promise of same-day review and on-time refill guarantees according to the captured source material.